Asilomar Pharmaceuticals Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Liquidation

Asilomar Pharmaceuticals General Information

Description

Developer of drugs to improve treatment of the central nervous system. The company has prototyped several anti-inflammatory agents to treat localized forms of neuropathic pain: Post-herpetic neuralgia, Trigeminal neuralgia, and Diabetic mononeuropathy.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Suite 400, PMB 309
  • New York, NY
  • United States
+1 (408)
Primary Industry
Drug Discovery
Acquirer
Manzanita Pharmaceuticals
Vertical(s)
Corporate Office
  • Suite 400, PMB 309
  • New York, NY
  • United States
+1 (408)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Asilomar Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Bankruptcy: Liquidation 01-May-2007 Completed Bankruptcy: Liquidation
1. Later Stage VC (Series A) 01-Aug-2003 Completed Product Development
To view Asilomar Pharmaceuticals’s complete valuation and funding history, request access »

Asilomar Pharmaceuticals Patents

Asilomar Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20040120891-A1 B-l-m where b is an agent capable of selectively binding to a nerve cell surface receptor, mediating absorption by the nerve cell; m is a moiety which performs a useful non-cytotoxic function when absorbed by a nerve cell; and l is a linker Inactive 05-Sep-2002
AU-2002243422-A1 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins Inactive 06-Nov-2000
CA-2436830-A1 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins Inactive 06-Nov-2000
EP-1349577-A2 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins Inactive 06-Nov-2000
WO-2002047730-A2 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins Inactive 06-Nov-2000 A61K47/6425
To view Asilomar Pharmaceuticals’s complete patent history, request access »

Asilomar Pharmaceuticals Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Asset Management Ventures Venture Capital Minority
Band of Angels Angel Group Minority
Lanfear Capital Venture Capital Minority
SBV Venture Partners Venture Capital Minority
Sears Capital Management Venture Capital Minority
To view Asilomar Pharmaceuticals’s complete investors history, request access »

Asilomar Pharmaceuticals FAQs

  • When was Asilomar Pharmaceuticals founded?

    Asilomar Pharmaceuticals was founded in 1995.

  • Where is Asilomar Pharmaceuticals headquartered?

    Asilomar Pharmaceuticals is headquartered in New York, NY.

  • What industry is Asilomar Pharmaceuticals in?

    Asilomar Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Asilomar Pharmaceuticals a private or public company?

    Asilomar Pharmaceuticals is a Private company.

  • What is Asilomar Pharmaceuticals’s current revenue?

    The current revenue for Asilomar Pharmaceuticals is .

  • How much funding has Asilomar Pharmaceuticals raised over time?

    Asilomar Pharmaceuticals has raised $2.8M.

  • Who are Asilomar Pharmaceuticals’s investors?

    Asset Management Ventures, Band of Angels, Lanfear Capital, SBV Venture Partners, and Sears Capital Management have invested in Asilomar Pharmaceuticals.

  • When was Asilomar Pharmaceuticals acquired?

    Asilomar Pharmaceuticals was acquired on 01-May-2007.

  • Who acquired Asilomar Pharmaceuticals?

    Asilomar Pharmaceuticals was acquired by Manzanita Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process